HomeAbout UsThe TeamTarget Data BaseNews or ReviewsPartners

OncoStem Biotherapeutics                       
Executive Leadership

Rudolph E Willis, M.D.
CEO / Cofounder

BA: Northwestern University
      Chemistry / Biology (honors)

MD: Washington University School of Medicine,
        St. Louis

Post Doc: NIH, National Cancer Institute -   
                 Laboratory of Tumor Cell Biology

Prior: Director of Clinical Trials subunit -
         Washington University School of
         Medicine, St. Louis

Faculty:Clinical Assistant Professor of  Medicine
              Drexel University College of Medicine

Senior Advisor

Scott M Kahn, Ph.D.
CSO / Cofounder

BA: Brandeis University
       Chemistry (honors), Biochemistry

Ph.D.: SUNY @ Stony Brook
           Biochemistry and Molecular Biology

Chairman, Biomarkers Council, International
Cancer Advocacy Network

Prior: Member, Columbia Herbert Irving
          Comprehensive Cancer Center

​Faculty Member, Dept. of Radiation Oncology;
Urology, Columbia University

Director of Basic Urologic Research, St. Luke's -
Roosevelt Hospital Center

Our Advisors
​Charles Karan Ph.D.,
Scientific Director
High Throughput Screening Center
JP Sultzburger Columbia Genome Center

Dr. Karan provides expertise in assay
development and execution, using state of the art screening tools. He is an expert in small molecule chemistry.
​Dr. Joseph Mo
CEO NAL Pharmaceuticals (private)
Founder of Nexmed, Inc. (Nasdaq NEXM)

NAL develops proprietary and improved drug delivery systems that exhibit enhanced patient compliance, safety, and/or efficacy.

Shi-Xian Deng, Ph.D.
Chemistry Group Coordinator

Organic Chemistry Collaborative Center (OCCC) Columbia Irving Inst. for Clinical and Translational Research

OCCC specializes in organic synthesis, drug discovery, and pharmacokinetic studies.
Since 2003, 7 patents have been licensed.

Marcia K. Horn, President / ​CEO
International Cancer Advocacy Network (ICAN)

International Cancer Advocacy Network is a 501(c)(3) tax-exempt charitable organization providing direct patient navigation for Stage IV cancer cases throughout the United States and in 53 countries. ICAN has assisted over 8,000 patients on an individual basis since its founding in 1996, and is highly experienced with patient needs, including molecular profiling and clinical trial placement.